Keywords
COVID-19, ABO, RhD, Blood type, Risk factors, Blood group, Red blood cells, Iraq
This article is included in the Emerging Diseases and Outbreaks gateway.
This article is included in the Coronavirus (COVID-19) collection.
This article is included in the DO NOT USE old GW area collection.
COVID-19, ABO, RhD, Blood type, Risk factors, Blood group, Red blood cells, Iraq
COVID-19 is caused by the newly identified severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which initiated a pandemic in early 20201,2. Following initial infections in Wuhan, Hubei Province of China, it has affected almost all countries in the world, resulting in a significant number of deaths (over 1.1 million until October 2020) and increased economic burden worldwide. The primary symptoms of COVID-19 include a fever, persistent cough, dyspnoea, thrombosis, myalgia, fatigue, and, in some cases, decreased white blood cell count and severe pneumonia, which requires mechanical ventilation and other intensive care support. Although the relationship between ABO blood types and various diseases is poorly understood, blood types have been reported to be associated with several diseases caused by organisms such as SARS-CoV-13, Helicobacter pylori4, hepatitis B virus5, Norwalk virus6, rotavirus and dengue virus, as well as malaria7. Similarly, the potential importance of ABO blood types in relevance to contracting COVID-19 has been sparsely reported. While some studies found no significant correlation between blood types and the impact of COVID-198–10, others have reported that people with O blood type are partially protected against COVID-19 infection and people with A or AB blood type are more susceptible to this disease11–16. This could be due to the presence of anti-A17 and/or anti-B antibodies in the circulation and their ability to bind to the spike proteins of the virus, thereby preventing them entering cells and proliferating. Notably, a genome wide association study has confirmed the potential involvement of the ABO blood group system in contracting COVID-1918. Although few studies have specifically established an association between RhD blood type and susceptibility to COVID-19, a recent study reported a high risk association between RhD+, COVID-19 infection and resulting deaths13. However, the robust correlation between the blood types specifically RhD and COVID-19 infection has not yet been fully established. Hence, we explored the potential association between blood types, particularly RhD and COVID-19 in a study population of Iraq.
The aim of this study was to analyse the relationship between the blood types and COVID-19 associated complications in a small population of Iraq. Therefore, in this study, we collected data (i.e. blood group, primary symptoms, previous risk factors, age, gender and outcomes, severity level of COVID-19) from the records of 5,668 COVID-19 patients (confirmed as positive by real-time polymerase chain reaction and this was considered as the key criteria for eligibility to be included in this study) who were admitted to Al-Hussein Teaching Hospital, Thi-Qar and Alkarama Teaching Hospital, Wasit in Iraq between March and June 2020. Blood type data, were collected from the same number of control (non-COVID-19) individuals from the same hospitals (using their records database) and matched by age and gender to the cases.
The sample size was based on the number of COVID-19 patients admitted in these two hospitals during the study period. The accuracy of data was thoroughly checked by healthcare professionals working in these hospitals and the authors prior to analysis. The individuals who were involved in data collection did not directly analyse the data. The data analysis (between COVID-19 and non COVID-19 groups) was performed by different authors using anonymised data in order to avoid any potential bias. All the statistical analyses were performed using Pearson’s Chi-square test and logistic regression models in R statistical package (www.r-project.org).
This study design, data collection and consent were approved by the ethical committee (Ref no: 00563477) at Thi-Qar Health Directorate, the Ministry of Health, Republic of Iraq, and all the data were anonymised prior to analysis. Informed verbal consent was obtained from all patients to use their records, and where patients were minor (below 18 years old), consent was obtained from their parents or legal guardians. Verbal consent instead of written consent was obtained as the hospitals were very busy, as a result of the pandemic. Appropriate permissions from the hospitals were also obtained to use the anonymised data for this study.
The COVID-19 population studied here consisted of 3691 (65.2%) males and 1977 (34.8%) females. According to age group: ≤10 years, 267 (4.7%); 11-20 years, 511 (9%); 21–30 years, 1781 (31.4%); 31–40 years, 1221 (21.5%); 41–50 years, 870 (15.3%); 51–60 years, 569 (10%); 61–70 years, 273 (4.8%); 71–80 years, 138 (2.4%); 81–90 years, 32 (0.6%); 90+ years, 6 (0.1%) (with the highest age being 100). The median age of the population was 33 years, and the most infected age group in this population was 21–30 years old.
Among COVID-19 patients, 1572 (27.7%) had blood type A (A+ = 1493; A- = 79), 1880 (33.2%) had B (B+ = 1653; B- = 227), 645 (11.4%) had AB (AB+ = 511; AB- = 134) and 1571 (27.7%) had O (O+ = 1495; O- = 76). The control population (5668, matched for age and sex) had a similar ratio of blood types [1454 (25.7%) people had A (A+ = 1405; A- = 49); 1792 (31.6%) had B (B+ = 1692; B- = 100); 411 (7.3%) had AB (AB+ = 366; AB- = 45); 2011 (35.5%) had O (O+ = 1976; O- = 35)]. Among the control population, O+ was the most common blood type, and O- was the least common type with others being small population groups except A+ and B+.
There is very strong evidence (X2 = 209.51, df = 8, p <0.0001) for association between blood groups and COVID-19 infection among the study population. Exploring this association further demonstrates that the proportion of COVID-19 patients with O+ blood type is significantly lower than the control population, suggesting that this blood type is protective against this disease. In contrast, A-, AB-, AB+, B- and O- have shown increased susceptibility to COVID-19 compared to the control population (Figure 1A). Notably, COVID-19 patients with A+ and B+ blood types did not show any significant difference in the proportion infected when compared to the control group (Figure 1B). The risk of contracting COVID-19 was higher among RhD- patients compared to the RhD+ patients [OR = 2.38, 95% CI (2.03, 2.79), p= 0.0001]. There is no evidence for association between gender and blood type among COVID-19 patients (X2 = 4.97, df = 7, p = 0.664).
(A) the frequency of different blood types in the study population. (B) the proportions of controls and COVID-19 cases within different blood types. (C) the Sankey plot shows the relationship between blood types and severity of COVID-19 among the study population.
The Sankey plot (Figure 1C) illustrates the association between different blood types and the severity of COVID-19 among patients (the severity level was classified according to the guidelines provided by the Ministry of Health in Iraq). In total, there were 77 patients classified as in ‘critical’ stage, and all of them died in hospital during treatment. A total of 90 patients were in the ‘severe’ category, of which only 4 recovered while the others died in hospitals. A further 4000 were in the ‘moderate’ category and 1501 patients were listed as ‘mild’. Based on our analysis, there was no significant association between blood types and the severity of disease among these patients.
There is evidence for the association of some clinical symptoms with certain blood types among COVID-19 patients when adjusted for age, gender, severity of disease and risk factors. For example, asthenia is significantly lower in people with blood type B+ compared to individuals with O+ [OR = 0.98, 95% CI (0.96, 0.99), p= 0.004]. Similarly, experiencing a headache was significantly lower in people with blood type AB+ compared to people with O+ [OR = 0.97, 95% CI (0.95, 0.99), p= 0.012]. It is noteworthy that the size of these effects is very small. There is no significant correlation between other clinical symptoms (such as fever, chills, cough, dyspnea, anosmia ageusia, loss of appetite, muscle ache, cyanosis, rhinorrhoea, sore throat, diarrhoea, nausea and vomiting) and blood types.
In total, 176 deaths were recorded in this study among COVID-19 patients. However, there is no evidence for association of blood types, including RhD, with death due to COVID-19 when adjustments were made for age, gender and risk factors (X2 = 0.037, df = 7, p = 0.999). The 172 patients who died were reported to have various preexisting health conditions as risk factors. For example, 63 patients had hypertension, 19 had type 2 diabetes and hypertension, 33 had only diabetes, 1 had type 2 diabetes with acute renal failure, 1 had type 2 diabetes with atherosclerosis and another had diabetes with chronic kidney disease. Notably, 18 patients had chronic obstructive pulmonary disease (COPD), 3 had COPD with diabetes, and one had COPD with hypertension. Another 3 patients had chronic kidney disease and 1 had chronic lung disease. In total, 17 patients had hypertension while 4 had acute renal failure and 4 had acute pulmonary conditions. Of the 5668 patients, only 37 were asymptomatic (hence fewer admission in hospitals) and others had one or more notable COVID-19 symptoms.
The ABO blood types are known to be associated with several human diseases3–7. Similar to previous studies12,13, here we report that O+ blood type provides partial protection against COVID-19. While the association between RhD blood type and various diseases has not been fully established yet, RhD+ has been reported to be associated with high infection and death rate among COVID-19 patients in a population in the USA13. In contrast to this previous study13, interestingly, we report the significance of RhD blood type in influencing the susceptibility to contract COVID-19 among this study population; i.e. people with RhD- blood were more susceptible to contract COVID-19 than people with RhD+ blood type. The mechanisms behind this protection/susceptibility are unclear and further research is warranted to unravel the underlying questions. Moreover, we emphasise that the association between blood types (ABO and RhD) and COVID-19 is likely to be based on numerous factors including (but not limited to) ethnicity, geographical location, nature of occupation and the exposure to infected patients.
University of Reading Research Data Archive: Blood types and their relationship with COVID-19 among a study population in Iraq, http://dx.doi.org/10.17864/1947.27819.
Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0).
We would like to thank Abbas J. Hadi from the Thi-Qar Directorate of Public Health, Al-Hussein Teaching Hospital, Thi-Qar and Alkarama Teaching Hospital, Wasit, Iraq for providing all the data used in this study and their constant support.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Partly
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Yes
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: tumor marker, IBD, COVID-19, Nephrology
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: haematology, platelets, thrombosis, endothelial cells
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 1 21 Jan 21 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)